Ashley R Bardon
Overview
Explore the profile of Ashley R Bardon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thuo N, Bardon A, Mogere P, Kiptinness C, Casmir E, Wairimu N, et al.
BMC Health Serv Res
. 2024 Oct;
24(1):1281.
PMID: 39448999
Background: In Africa, dispensing oral HIV pre-exposure prophylaxis (PrEP) within already strained public health facilities has led to prolonged waiting periods and suboptimal experiences for clients. We sought to explore...
2.
Ortblad K, Bardon A, Mogere P, Kiptinness C, Gakuo S, Mbaire S, et al.
JAMA Netw Open
. 2023 Jun;
6(6):e2318590.
PMID: 37318803
Importance: Daily oral HIV preexposure prophylaxis (PrEP) delivery requires quarterly clinic visits for HIV testing and drug refilling that are costly to health systems and clients. Objective: To evaluate whether...
3.
Ngure K, Ortblad K, Mogere P, Bardon A, Thomas K, Mangale D, et al.
Lancet HIV
. 2022 Jul;
9(7):e464-e473.
PMID: 35777410
Background: Oral pre-exposure prophylaxis (PrEP) for HIV prevention is highly effective and is being implemented at scale at health clinics throughout sub-Saharan Africa. However, barriers to clinic-based PrEP delivery remain....
4.
Bardon A, Dorward J, Sookrajh Y, Sayed F, Quame-Amaglo J, Pillay C, et al.
BMJ Open
. 2021 Oct;
11(10):e050116.
PMID: 34610939
Introduction: Substantial improvements in viral suppression among people living with HIV (PLHIV) are needed to end the HIV epidemic, requiring extensive scale-up of low-cost HIV monitoring services. Point-of-care (POC) tests...
5.
Olanrewaju A, Sullivan B, Bardon A, Lo T, Cressey T, Posner J, et al.
Virol J
. 2021 Apr;
18(1):77.
PMID: 33858461
Objective: Maintaining adequate drug adherence is crucial to ensure the HIV prevention benefits of pre-exposure prophylaxis (PrEP). We developed an enzymatic assay for rapidly measuring tenofovir-diphosphate (TFV-DP) concentrations-a metabolite that...
6.
Bardon A, Simoni J, Layman L, Stekler J, Drain P
AIDS Res Ther
. 2020 Aug;
17(1):50.
PMID: 32762713
Background: Real-time, objective measures of adherence to antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are needed to better assess adherence levels and to expedite clinical response for those with suboptimal...
7.
Drain P, Bardon A, Simoni J, Cressey T, Anderson P, Sevenler D, et al.
Curr HIV/AIDS Rep
. 2020 Jul;
17(5):487-498.
PMID: 32627120
Purpose Of Review: In this report, we review the need for point-of-care (POC) or near real-time testing for antiretrovirals, progress in the field, evidence for guiding implementation of these tests...
8.
Hoffman R, Balakasi K, Bardon A, Siwale Z, Hubbard J, Kakwesa G, et al.
AIDS
. 2019 Nov;
34(3):475-479.
PMID: 31764076
Background: Little is known about the proportion of HIV-positive clients on antiretroviral therapy (ART) who meet stability criteria for differentiated service delivery (DSD) models. We report the proportion of ART...